Metraipolis › archive › dc_50001612fccf
Comparative Mechanistic Insights and Therapeutic Potential of Pembrolizumab, Durvalumab, and Ipilimumab as Immune Checkpoint Inhibitors in the Targeted… — Europe PMC PMID:40940902
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/40940902
- DOI
- 10.3390/cancers17172805
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-10T08:06:47.530Z
- SHA-256 of the archived text
de3896579a5a6d10379cdc48508e02b318a1906c706ab1cac380797114716975- Stable URL of this page
https://metraipolis.com/documento/dc_50001612fccf
How to cite
Comparative Mechanistic Insights and Therapeutic Potential of Pembrolizumab, Durvalumab, and Ipilimumab as Immune Checkpoint Inhibitors in the Targeted… — Europe PMC PMID:40940902 — Europe PMC (en), https://europepmc.org/article/MED/40940902 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_50001612fccf (Metraipolis archive dc_50001612fccf, sha256 de3896579a5a6d10379cdc48508e02b318a1906c706ab1cac380797114716975)
BibTeX
@misc{dc50001612fccf,
title = {Comparative Mechanistic Insights and Therapeutic Potential of Pembrolizumab, Durvalumab, and Ipilimumab as Immune Checkpoint Inhibitors in the Targeted… — Europe PMC PMID:40940902},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/40940902},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_50001612fccf; sha256 de3896579a5a6d10379cdc48508e02b318a1906c706ab1cac380797114716975},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40940902. Agents can read the archived copy with the MCP tool read_document.